MedTrace Logo

Observational Post-authorization Studies Carboplatin, Paclitaxel and Bevacizumab

NCT01814163 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2013-03-19

No results posted yet for this study

Summary

This is a pharmacogenomic study with carboplatin, paclitaxel and bevacizumab as first line therapy in patients with non-squamous advanced non-small cell lung cancer.

Conditions

  • Nonsquamous Nonsmall Cell Neoplasm of Lung

Interventions

DRUG

paclitaxel, carboplatin and bevacizumab

Paclitaxel 200 mg/m2, carboplatin area under curve (AUC) 6 mg/ml/min plus bevacizumab 15 mg/kg on day 1, every 21 days. Total number of cycles: 6. After 6 cycles bevacizumab on monotherapy until progression

Sponsors & Collaborators

  • Spanish Lung Cancer Group

    lead OTHER

Principal Investigators

  • Bartomeu Massutí, MD · H. Gen. Univ.Alicante

  • Carlos Camps, MD · H. Gen. Univ. Valencia

  • Javier de Castro, MD · H. La Paz

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-02-28
Primary Completion
2013-02-28
Completion
2013-02-28

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01814163 on ClinicalTrials.gov